Download PDF
Dtsch Med Wochenschr 2018; 143(03): 169-173
DOI: 10.1055/s-0043-124831
Klinischer Fortschritt
Nephrologie
© Georg Thieme Verlag KG Stuttgart · New York

Chronisches Nierenversagen – Update 2018

Chronic Kidney Disease – Update 2018
Markus Ketteler
1   Medizinische Klinik und Poliklinik 1, Schwerpunkt Nephrologie, Universitätsklinikum Würzburg
,
Christoph Wanner
2   Medizinische Klink III, Nephrologische Abteilung, Klinikum Coburg
› Author Affiliations
Further Information

Publication History

Publication Date:
06 February 2018 (online)

Also available at
    Permissions and Reprints

Was ist neu?

SGLT2-Hemmung bei diabetischer und nicht-diabetischer Nierenerkrankung Die CANVAS-Programm-Studie hat mit Canagliflozin die Nephroprotektion, welche mit Empagliflozin publiziert wurde (EMPA-REG-Outcome-Studie), bestätigt. Die Therapie mit Liraglutide in der LEADER Studie suggeriert Nephroprotektion über eine Reduktion der Albuminurie und geringerem eGFR-Abfall in Subgruppen/Stadien der diabetischen Nierenerkrankung.

KDIGO-CKD-MBD-Leitlinien-Update 2017 Im Juli 2017 erfolgte ein Update der KDIGO (Kidney Disease: Improving Global Outcomes) -2009-Leitlinie zur Diagnostik und Therapie der Störungen des Mineral- und Knochenhaushalts bei chronischen Nierenerkrankungen. Änderungen betrafen die Knochendichtemessung, die Therapie von Hyperphosphatämie und Hyperparathyreoidismus im Prädialysestadium und eine Warnung vor exzessiver Kalziumexposition.

Ein neues parenterales Kalzimimetikum Zwei Phase-III-Studien zum Einsatz eines neuen parenteralen Kalzimimetikums (Etelcalcitid) wurden publiziert.

What is new?

SGLT2-inhibition in diabetic and non-diabetic kidney disease The CANVAS Program Collaborative Group study confirmed nephroprotective actions by canagliflocin comparable to empagliflozin as published in the EMPA-REG Outcome study. Treatment with Liraglutide (LEADER study) also suggests nephroprotection via albuminuria reduction a decreased eGFR decline in subgroups and depending on stages of diabetic nephropathy.

KDIGO CKD-MBD Guideline Update 2017 In July 2017, an update of the KDIGO (Kidney Disease: Improving Global Outcomes) 2009 guideline on diagnostic and treatment chronic kidney disease – mineral and bone disorders (CKD-MBD) was published. Changes focused on the judgement of bone mineral density measurements, therapy of hyperphosphatemia and secondary hyperparathyroidism in CKD patients not on dialysis and on advising caution concerning excess calcium exposition.

A novel parenteral calcimimetic Two phase 3 studies on the use of a new parenteral calcimimetic drug (etelcalcitide) were published in 2017.

Schlüsselwörter

Chronische Nierenerkrankung - Störungen des Mineral- und Knochenstoffwechsels - Kalzimimetika - Diabetische Nierenerkrankung - SGLT2-Inhibitoren - Liraglutid

Key words

chronic kidney disease (CKD) - mineral and bone disorders (MBD) - calcimimetics - diabetic kidney disease - SGLT2 inhibitors - liraglutide
 

  • Literatur

  • 1 Zinman B, Wanner C, Lachin JM. et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015; 373: 2117-2128
    CrossrefPubMedGoogle Scholar
  • 2 Wanner C, Inzucchi SE, Lachin JM. et al. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med 2016; 375: 323-334
    CrossrefPubMedGoogle Scholar
  • 3 Cherney DZI, Zinman B, Inzucchi SE. et al. Effects of empagliflozin on the urinary albumin-to-creatinine ratio in patients with type 2 diabetes and established cardiovascular disease: an exploratory analysis from the EMPA-REG OUTCOME randomised, placebo-controlled trial. Lancet Diab Endo 2017; 5: 610-621
    PubMedGoogle Scholar
  • 4 Wanner C. EMPA-REG OUTCOME: The Nephrologist’s Point of View. Am J Med 2017; 130: 63-72
    PubMedGoogle Scholar
  • 5 Neal B, Perkovic V, Mahaffey KW. et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017; 377: 644-657
    CrossrefPubMedGoogle Scholar
  • 6 Wanner C, Lachin JM, Inzucchi SE. et al. Empagliflozin and clinical outcomes in patients with type 2 diabetes mellitus, established cardiovascular disease, and chronic kidney disease. Circulation 2017; DOI: 10.1161/CIRCULATIONAHA.117.028268.
    CrossrefPubMedGoogle Scholar
  • 7 Ketteler M, Block GA, Evenepoel P. et al. Executive summary of the 2017 KDIGO Chronic Kidney Disease–Mineral and Bone Disorder (CKD-MBD) Guideline Update: what’s changed and why it matters. Kidney Int 2017; 92: 26-36
    CrossrefPubMedGoogle Scholar
  • 8 Iimori S, Mori Y, Akita W. et al. Diagnostic usefulness of bone mineral density and biochemical markers of bone turnover in predicting fracture in CKD stage 5D patients--a single-center cohort study. Nephrol Dial Transplant 2012; 27: 345-351
    CrossrefPubMedGoogle Scholar
  • 9 Naylor KL, Garg AX, Zou G. et al. Comparison of fracture risk prediction among individuals with reduced and normal kidney function. Clin J Am Soc Nephrol 2015; 10: 646-653
    CrossrefPubMedGoogle Scholar
  • 10 West SL, Lok CE, Langsetmo L. et al. Bone mineral density predicts fractures in chronic kidney disease. J Bone Miner Res 2015; 30: 913-919
    CrossrefPubMedGoogle Scholar
  • 11 Yenchek RH, Ix JH, Shlipak MG. et al. Bone mineral density and fracture risk in older individuals with CKD. Clin J Am Soc Nephrol 2012; 7: 1130-1136
    CrossrefPubMedGoogle Scholar
  • 12 Block GA, Kilpatrick RD, Lowe KA. et al. CKD-mineral and bone disorder and risk of death and cardiovascular hospitalization in patients on hemodialysis. Clin J Am Soc Nephrol 2013; 8: 2132-2140
    CrossrefPubMedGoogle Scholar
  • 13 Block GA, Wheeler DC, Persky MS. et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23: 1407-1415
    CrossrefPubMedGoogle Scholar
  • 14 Hill KM, Martin BR, Wastney ME. et al. Oral Kalzium carbonate affects Kalzium but not phosphorus balance in stage 3–4 chronic kidney disease. Kidney Int 2013; 83: 959-966
    CrossrefPubMedGoogle Scholar
  • 15 Moe SM, Chertow GM, Parfrey PS. et al. Cinacalcet, fibroblast growth factor-23, and cardiovascular disease in hemodialysis: The evaluation of cinacalcet HCl therapy to lower cardiovascular events (EVOLVE) trial. Circulation 2015; 132: 27-39
    CrossrefPubMedGoogle Scholar
  • 16 Di Iorio B, Bellasi A, Russo D. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012; 7: 487-493
    CrossrefPubMedGoogle Scholar
  • 17 Di Iorio B, Molony D, Bell C. et al. Sevelamer versus Kalzium carbonate in incident hemodialysis patients: results of an open-label 24-month randomized clinical trial. Am J Kidney Dis 2013; 62: 771-778
    CrossrefPubMedGoogle Scholar
  • 18 Thadhani R, Appelbaum E, Pritchett Y. et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012; 307: 674-684
    CrossrefPubMedGoogle Scholar
  • 19 Wang AY, Fang F, Chan J. et al. Effect of paricalcitol on left ventricular mass and function in CKD--the OPERA trial. J Am Soc Nephrol 2014; 25: 175-186
    CrossrefPubMedGoogle Scholar
  • 20 Block GA, Bushinsky DA, Cunningham J. et al. Effect of Etelcalcetide vs Placebo on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: Two Randomized Clinical Trials. JAMA 2017; 317: 146-155
    CrossrefPubMedGoogle Scholar
  • 21 Block GA, Bushinsky DA, Cheng S. et al. Effect of Etelcalcetide vs Cinacalcet on Serum Parathyroid Hormone in Patients Receiving Hemodialysis With Secondary Hyperparathyroidism: A Randomized Clinical Trial. JAMA 2017; 317: 156-164
    CrossrefPubMedGoogle Scholar